PUVA therapy for psoria Photochemotherapy combines a natural or artificial light to achi effect not produced by the ch separately. Its use in psoriasis w in this journal over 4 years ago Warin 1979) . Extracts of Ammi X 'used topically and orally since bil Nile Valley to induce inflammati( conjunction with sunlight to tr4 The isolation of 8-methoxypsc from the plant allowed clinical s (Lerner et al. 1953 ) and experime demonstrated the inhibition of D various tissues exposed to 8-MOI ultraviolet light (UVA) (Epsteii 1970 , Baden et al. 1972 . Vario confirmed the ability of topical p by UVA to induce resolution of I (Tronnier & Schule 1973 , Walter the successful use of oral 8-MO followed (Parrish et al. 1974) , the development of a high-poten PUVA had arrived.
Many studies have since confir of oral PUVA therapy in psoi cooperative multicentre trials in E et al. 1981 ) and the USA (Me] Roenigk et al. 1979 ) have achi similar results. About 60% of completely cleared and another 31 improved. Less than 10% fail to i adversely.
Treatment consists of the ora of 0.6 mg/kg of 8-MOP. Two h4 psoralen concentrations in the sk the whole body is irradiated with of UVA, starting with 1.0 J cm2 protected. The treatment is give times weekly and the UVA dose s to 7.0 J cm2 or more. In about the European study, a mean of 24 needed over 5 or 6 weeks to a to J. Rather higher doses and more 10 to 12 weeks were given in the study, probably because 3 rath( ments per week were favoured maintenance therapy, once optin been achieved, is controversial every 2 to 4 weeks may succe remission.
Minor side effects are co erythema, skin tenderness or occur in up to 30% of patients. MOP induced nausea are also cl 0 1 41-0768/84/070537-03/$01.00/0 Miller & Munro 1980). Cataracts and corneal opacities have been chemical with induced in albino mice and pigmented guinea pigs ieve a beneficial by massive PUVA dosage (Cloud et al. 1961) . emical or light Parrish et al. (1979) could not find cataracts in as first reviewed rabbits after 18 months of PUVA and no t(Vella Briffa & cataracts have been reported in humans (Back et majus have been al. 1980). However, bilateral punctate cortical blical days in the opacities, not present prior to therapy, have been on of the skin in reported rarely (Kasick et al. 1982 , Lerman eat leukoderma. 1982 . )ralen (8-MOP)
SIS
Reservations regarding the long-term safety of tudies in vitiligo PUVA have focused on a possible carcinogenic ntal work which hazard, either by direct action on the epidermis )NA synthesis in or indirectly via the immune system. UVA-P and long-wave activated psoralen damages DNA by combining n & Fukuyama covalently with the pyrimidine bases of nucleic us reports soon acids, enabling opposing strands of the DNA to Isoralen followed be cross-linked. However, interference with DNA psoriatic plaques synthesis and thus the epidermal hyperproliferaet al. 1973) and tion of psoriasis may not be the only mode of IP (P) and UVA action. Toxic effects on Langerhans' and other iade possible by immunocompetent cells in the skin may well be cy UVA source. relevant. Reduction in circulating T-lymphocyte numbers and function is well documented rmed the efficacy (Morison et al. 1983 ) but there are reports of riasis and huge previously depressed T-cell numbers returning to ,urope (Henseler normal during PUVA therapy (Guilhou et al. Iski et al. 1977 , Haftek et al. 1979 . A reduction in ieved essentially circulating helper/inducer T cells has been patients can be associated with long-term therapy (Moscicki et 0% substantially al. 1982) . Inhibition of lymphocyte DNA synimprove or react thesis occurs, and the effect has been demonstrated to be an immediate one on circulating 1 administration lymphocytes in vivo (Friedmann & Rogers 1980) . Ours later, when The effects of epidermal leukostatic factors are (in are maximal, depressed (Mizuno et al. 1979 ) but granulocyte measured doses and monocyte locomotion are apparently 2, the eyes being unaffected (Silny et al. 1980) . Delayed hypern three or four sensitivity responses are undoubtedly reduced teadily increased and delayed (Vella Briffa et al. 1981 , Morison et 3200 patients in al. 1983 , perhaps due to Langerhans' cell 0 treatments was depletion or damage in the irradiated skin otal of about 100 (Friedmann 1981 , Okamoto & Horio 1981 . treatments over It is undisputed that solar ultraviolet radiation US multicentre is a major aetiological factor in squamous and er than 4 treat-basal cell carcinoma and malignant melanoma in 1. The value of humans. Psoralens are known to be mutagenic nal response has (Bridges 1978) and DNA damage has been but treatment induced by PUVA both in bacterial and mammassfully maintain lian cell cultures and in human lymphocytes (Bridges 1978) . Tumours have been induced in tmmon. Diffuse the skin of hairless albino mice by PUVA frank 'sunburn' exposure using both 8-MOP and 5-MOP (Young Pruritus and 8et al. 1983) . PUVA therapy accelerated the ommon. A mild development of skin tumours in patients with xeroderma pigmentosum (Reed 1976) and had an obvious promoter (co-carcinogenic) effect in a patient, previously exposed to X-irradiation, arsenic and several cytotoxic drugs, who developed 15 basal or squamous cell carcinomata, the first within 21 months of onset of PUVA therapy (Baker et al. 1981) .
Several groups have reported on the incidence of tumours in groups of PUVA-treated patients. No excess over expected rates was found in 631 US patients over 4 years (Roenigk & Caro 1981) or in 250 Swedish patients followed up for up to 7 years (Ros et al. 1983) . Higher than expected rates and altered ratios of squamous to basal carcinomata were found in another multicentre US study (Stern et al. 1979) , in 418 Austrian patients (Honigsmann et al. 1980 ) and in Australian (Lobel et al. 1981) and Danish series (Lindskov 1983). However, it is clear from these reports that tumours occurred largely in patients previously exposed to known carcinogenic hazards, i.e. arsenic and radiotherapy, or excessive sun exposure. Recent UK experience also points to a hazard in patients not so exposed (Reshad et al. 1984) and isolated reports of multiple Bowenoid lesions, kerato-acanthomata and squamous carcinomata support this conclusion (Tam et al. 1979 , Hofmann et al. 1979 , Brown et al. 1980 , Reshad et al. 1984 . Very recently, US follow-up data on 1380 patients treated for an average of almost 6 years demonstrated a clear dose/risk relationship for squamous carcinoma (but not for basal cell carcinoma) independent of prior exposure to other known carcinogens (Stern et al. 1984) .
PUVA-induced lentigines may demonstrate cytologically atypical melanocytes (Rhodes et al. 1983) , and malignant melanoma in situ has been reported in two psoriatic patients who had received 324 and 2800 joules cm-2 respectively (Marx et al, 1983) . One of the writer's patients has recently developed a nodular malignant melanoma (in preparation). The significance of these observations is not yet clear but they demand vigilance on the part of clinicians using PUVA therapy. There is no evidence of any internal tumour hazard and there are no reports of tumours induced by topical use of psoralens. Synthesis of clinical and experimental data suggests that there is a small but real photocarcinogenic hazard from PUVA therapy and that this is dose-related and compounded by previous exposure to known risk factors.
-PUVA is remarkably non-toxic for systemic organs, and regular blood, renal or liver function tests are not necessary but should be carried out occasionally as clinical circumstances demand.
PUVA can be combined with other forms of treatment for psoriasis. Dithranol and PUVA have been used together (Cripps & Lowe 1979) and sequentially (van de Kerkhof & Mali 1981) . The most potent and effective combined regimen employs PUVA in conjunction with the oral synthetic retinoid, etretinate, and its use gives results superior to those achieved by PUVA alone as well as having a UVA-sparing effect (Thivolet et al. 1981 , Wolff & Fritsch 1982 . 'RE-PUVA' is particularly valuable in palmo-plantar psoriasis and in generalized erythrodermic and pustular forms of the disease (Wolff & Fritsch 1982) .
Since PUVA using oral 8-MOP was introduced, the topical application of the psoralen has been relegated to secondary importance. PUVA using an emulsion or lotion of 8-MOP followed by UVA irradiation 30 to 60 minutes later has a place in the management of recalcitrant, very localized psoriasis which is usually a problem on the palms or soles. In particular, palmo-plantar pustular psoriasis has been so treated (Lakshmipathi et al. 1977) . A controlled trial, in which one hand or foot only was treated, has unequivocally demonstrated efficacy (Murray & Warin 1979) but response tends to be slow and incomplete, up to 40 treatments being necessary in many patients (Wilkinson et al. 1979 , Abel et al. 1980 . A decade after its advent, PUVA has established itself as an effective, pleasant and, in the short and medium terms, safe therapy for psoriasis. Its long-term safety remains to be established. Almost certainly PUVA is photocarcinogenic and the problem lies in the quantification of this hazard; another ten years or more will be needed to provide the answers. In the USA, Food and Drug Administration approval for treatment of severe psoriasis was granted in May 1982. In the UK, official approval is still withheld and no psoralen preparation has a UK product licence. Nevertheless, PUVA is widely used in NHS and university hospitals throughout the UK, the drug being imported and used on a 'named patient' basis.
At present, prudence dictates that PUVA should be used only for severe psoriasis which is intolerable to the patient and which has resisted conventional therapy. In patients over the age of 50 years, it can certainly be used in such situations. The younger the patient, the more compelling should be the indications. The risks of PUVA must always be weighed against those of cytotoxic drugs (methotrexate and hydroxyurea are chiefly used) or etretinate. Despite the undoubted vaue of these last-named agents, no dermatologist who looks after patients with severe forms of psoriasis would like to be without the PUVA weapon.
Harvey Baker Consultant Dermatologist
The London Hospital Drugs and exposure treatment in phobic and obsessive-compulsive disorders'
Several classes of drugs have been used with behavioural treatments in phobic and obsessivecompulsive disorders (Marks 1981) . Sedatives like barbiturates, benzodiazepines and alcohol have not been found to be of lasting benefit and in high doses may actually be counterproductive because what is learned under the influence of the drug usually fails to transfer to the drug-free state. Beta-blockers too have not had durable effects. Antidepressants seem to be of greater value.
There have been at least 19 controlled studies of the use of antidepressants for phobic and obsessive-compulsive problems (Marks 1983) . The results suggest that antidepressants usually have their main effects when phobias and 'Based on presentation to Section of Psychiatry, 7 February 1983 0 141-0768/84/070539-02/$O1 .00/0 co 1984 The Royal Society of Medicine
